Все аптеки Украины
Киев (адрес не указан)

Список использованной литературы

  • 1. Дзяк Г.В. Подагра: капкан метаболічних проблем/Г.В. Дзяк, Т.А. Хомазюк — Дніпропетровськ: ООО «Роял Принт», 2010. — 112 с.
  • 2. Коваленко В.М., Корнацький В.М. (ред.) Актуальні проблеми здоров’я та мінімізація їх в умовах збройного конфлікту в Україні (Посібник). — К., 2018. — 215 с.
  • 3. Коваленко В.М., Шуба Н.М. (ред.) Національний підручник з ревматології. — К., МОРІОН, 2013. — 672 с.
  • 4. Borghi C., Rosei E.A., Bardin T., Dawson J., Dominiczak A., Kielstein J.T. et al. Serum uric acid and the risk ofcardiovascular and renal disease. J. Hypertens. 2015; 33: 1729–1741.
  • 5. Bernal J.A., Quilis N., Andrés M., Sivera F., Pascual E. Gout: optimizing treatment to achieve a disease cure//Ther. Adv. Chronic Dis. 2016; 7 (2): 135–144.
  • 6. Cicero A.F.G., Salvi P., D’Addato S., Rosticci M., Borghi C. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: Data from the Brisighella Heart Study. J. Hypertens. 2014; 32: 57–64.
  • 7. De Becker B., Borghi C., Burnier M., van de Borne P. Uric Acid and Hypertension: An Update. Esc. Scientifc Newsletter. Update on Hypertension Management 2018; 19, № 69.
  • 8. EULAR. 10 things you should know about rheumatic diseases fact sheet. Available at: https://www.eular.org/myUploadData/files/10thingsonRD.pdf [Last accessed April 2018].
  • 9. Feig D.I. Serum uric acid and the risk of hypertension and chronic kidney disease. Curr. Opin. Rheumatol. 2014; 26:176–185.
  • 10. Gois P., Erdm S. Pharmacotherapy for hyperuricemia in hypertensive patients (Review). Cochrane Database Syst. Rev. Published Online First: 2017.
  • 11. Gunawardhana L., McLean L., Punzi H.A., Hunt B., Palmer R.N., Whelton A. et al. Effect of Febuxostat onambulatory blood pressure in subjects with hyperuricemia and hypertension: A Phase 2 randomizedplacebo-controlled study. J. Am. Heart. Assoc. 2017; 6. doi:10.1161/JAHA.117.006683.
  • 12. Khanna D., Fitzgerald J., Khanna P., Bae S., Singh M., Neogi T. et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia//Arthritis Care Res. 2012; 64: 1431–1446.
  • 13. Mandal A.K., Mount D.B. The molecular physiology of uric acid homeostasis//Annu. Rev. Physiol. 2015; 77:323–334.
  • 14. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative//Ann. Rheum. Dis. 2014; 73: 328–333.
  • 15. Neogi T. Gout. Engl. J. Med. 2011; 364: 443–452. doi:10.1056/NEJMcp100112. http://www.nejm.org/doi/full/10.1056/NEJMcp1001124.
  • 16. Ohta Y., Ishizuka A., Arima H., Hayashi S., Iwashima Y., Kishida M. et al. Effective uric acid-loweringtreatment for hypertensive patients with hyperuricemia. Hypertens. Res. 2017; 40: 259–263.
  • 17. Qaseem A., Harris R.P., Forciea M.A. Management of acute and recurrent gout: a clinical practice guideline from the american college of physicians//Ann. Intern. Med. 2017; 166 (1): 58–68.
  • 18. Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study//Ann. Rheum. Dis. 2013; 72: 826–830.
  • 19. Richette P., Clerson P., Périssin L., Flipo R., Bardin T. Revisiting comorbidities in gout: a cluster analysis//Ann. Rheum. Dis. 2015; 74: 142–147.
  • 20. Richette P., Doherty M., Pascual E. et al. 2016 updated EULAR evidence-based recommendations for themanagement of gout. Ann. Rheum. Dis. 2017; 76: 29–42.
  • 21. Richette P., Doherty M., Pascual E., Barskova V., Becce F., Castaneda-Sanabria J. EULAR evidence-based recommendations for the management of gout//Ann. Rheum. Dis. 2017; 76 (1): 29–42.
  • 22. Ridker P.M., Everett B.M., Thuren T. et al. Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 2017; 377 (12): 1119–1131.
  • 23. Solomon D.H., Glynn R.J., MacFadyen J.G. et al. Serum urate, gout, and cardiovascular disease in a randomized controlled trial of canakinumab: A CANTOS secondary analysis. EULAR 2018; Amsterdam: Abstract OP0014.
  • 24. van der Heijde D. et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Ann. Rheum. Dis. 2018.
    doi:10.1136/annrheumdis-2017–212565 [Epub ahead of print].
  • 25. White W.B., Saag K.G., Becker M.A., Borer J.S., Gorelick P.B., Whelton A., Hunt B., Castillo М. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N. Engl. J. Med. 2018 Mar 29; 378 (13): 1200–1210. doi: 10.1056/NEJMoa1710895.
  • 26. Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P. et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)//Ann. Rheum. Dis. 2006; 65: 1312–1324.